Clinical Trials
Open Clinical Trials
| Full Title | Phase I/II Trial of Induction Carboplatin/Paclitaxel with Bevacizumab followed by Concurrent Thoracic Conformal Radiation Therapy with Carboplatin/ Paclitaxel, Bevacizumab and Erlotinib in Stage III A/B Non-small Cell Lung Cancer |
| Trial Type | Therapeutic |
| Disease | NSCL |
| PI | Scott Gettinger |
| Primary Objective | PTo establish the dose of both bevacizumab and erlotinib given concurrently with low-dose weekly carboplatin/paclitaxel and 74 Gy of TCRT. |
| Target Population | Stage III A/B NSCLC suitable and appropriate for combined modality therapy; ECOG performance Status 0-1; FEV1 ¿ 1 liter; Squamous cell patients are allowed assuming they have no hemoptysis and do not have central invasive lesions which abut major blood |
| Exclusion | Current, recent or planned participation in an experimental durg study other than LCCC 0511; Blood pressure . 150/100mmHg on three separate occasions; Unstable angina, NYHA grade |
| FDA Phase | I-II |
For further information on this clinical trial, please call the Yale Cancer Center Clinical Trials Office at 203-785-5702. | |